<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-41577" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ivabradine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Reed</surname>
            <given-names>Mirembe</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kerndt</surname>
            <given-names>Connor C.</given-names>
          </name>
          <aff>Spectrum Health/Michigan State University College of Human Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nicolas</surname>
            <given-names>Diala</given-names>
          </name>
          <aff>Steward St. Elizabeth's Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mirembe Reed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Connor Kerndt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Diala Nicolas declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-41577.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ivabradine is FDA-approved in the United States for use in patients with symptoms due to stable heart failure and an ejection fraction of 35% or less to reduce their risk of hospital admission for worsening heart failure. Ivabradine blocks the channel responsible for the cardiac pacemaker current, I(f), which regulates heart rate. This results in prolonged diastolic time and reduced heart rate. This activity covers ivabradine, including mechanism of action, pharmacology, adverse event profiles, eligible patient populations, contraindications, monitoring, and highlights the role of the interprofessional team in the management of ivabradine therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the mechanism of action of ivabradine</p></list-item><list-item><p>Identify the indications for initiating therapy with ivabradine.</p></list-item><list-item><p>Outline the adverse event profile of ivabradine, along with any possible contraindications to its use.</p></list-item><list-item><p>Explain the importance of collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients receiving ivabradine in heart failure.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41577&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41577">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-41577.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ivabradine&#x000a0;is&#x000a0;FDA-approved in the United States&#x000a0;for use in patients with symptoms due to stable heart failure&#x000a0;and an ejection fraction of 35% or less to reduce their risk of hospital admission for worsening heart failure.<xref ref-type="bibr" rid="article-41577.r1">[1]</xref><xref ref-type="bibr" rid="article-41577.r2">[2]</xref><xref ref-type="bibr" rid="article-41577.r3">[3]</xref></p>
        <p>Patients on ivabradine therapy should have a resting heart rate&#x000a0;of at least 70 beats per minute and must be in normal sinus rhythm. They should also be on their maximum tolerated beta-blocker or have a contraindication to beta-blocker use.</p>
        <p>In Europe, ivabradine is indicated in the treatment of heart failure and chronic stable angina.</p>
      </sec>
      <sec id="article-41577.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Ivabradine blocks the channel responsible for the cardiac pacemaker current, I(f), which regulates heart rate. This results in prolonged diastolic time and reduced heart rate.<xref ref-type="bibr" rid="article-41577.r4">[4]</xref></p>
        <p>Rapid resting heart rate can lead to detrimental effects on left ventricular function and has been associated with negative outcomes in patients with cardiovascular disease. Therefore, reducing resting heart rate to reduce cardiovascular morbidity and mortality&#x000a0;is a therapeutic target among drug manufacturers. Ivabradine reduces heart rate but does not affect&#x000a0;myocardial contraction, relaxation,&#x000a0;or ventricular repolarization.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-41577.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Ivabradine is available as tablets to be taken by mouth.</p>
        <list list-type="bullet">
          <list-item>
            <p>The initial&#x000a0;dose should&#x000a0;be&#x000a0;5 mg, twice a day.</p>
          </list-item>
          <list-item>
            <p>The dose can be adjusted after 2 weeks based on the heart rate.</p>
          </list-item>
          <list-item>
            <p>The maximum dose is 7.5 mg, twice a day.</p>
          </list-item>
          <list-item>
            <p>Patients with conduction defects or bradycardia can be initiated on 2.5 mg, twice a day.</p>
          </list-item>
          <list-item>
            <p>The reduction in heart rate&#x000a0;depends on the baseline heart rate and the ivabradine dose.</p>
          </list-item>
        </list>
        <p>
<bold>Dose Adjustment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>If the heart rate&#x000a0;is more than&#x000a0;60, increase the dose by 2.5 mg, twice a day, up to 7.5 mg twice a day.</p>
          </list-item>
          <list-item>
            <p>If the heart rate is 50-60 bpm, continue the&#x000a0;current dose.</p>
          </list-item>
          <list-item>
            <p>If the heart rate is less than 50 or the patient is experiencing symptoms of bradycardia, decrease the dose by 2.5 mg twice a day. If the dose is 2.5 mg twice daily, stop therapy.</p>
          </list-item>
        </list>
        <p>
<bold>Clinical Evidence</bold>
</p>
        <p>The SHIFT trial was a double-blind, placebo-controlled study of patients with symptomatic heart failure,&#x000a0;ejection fraction (EF) less than or equal to 35%, in sinus rhythm with a heart rate of at least 70 beats per minute, who had been admitted for heart failure within the past year and were on stable heart failure treatment including beta-blockers. Patients received ivabradine titrated to 7.5 mg&#x000a0;twice a day&#x000a0;or placebo. The&#x000a0;goal was to determine if ivabradine would&#x000a0;decrease hospitalizations and/or mortality due to heart failure.&#x000a0;Ivabradine reduced the primary endpoint, which was a composite of&#x000a0;hospital admissions due to heart failure and mortality. Bradycardia and visual adverse effects (phosphenes) occurred more&#x000a0;in patients&#x000a0;receiving ivabradine&#x000a0;than those in the placebo group.<xref ref-type="bibr" rid="article-41577.r5">[5]</xref><xref ref-type="bibr" rid="article-41577.r6">[6]</xref><xref ref-type="bibr" rid="article-41577.r7">[7]</xref><xref ref-type="bibr" rid="article-41577.r8">[8]</xref></p>
        <p>The BEAUTIFUL trial&#x000a0;was a randomized, placebo-controlled, multinational trial to test whether reducing heart rate with ivabradine affected cardiovascular morbidity and mortality in patients with coronary artery disease and EF less than 40%.&#x000a0;Patients had a resting heart rate of at least 60 beats per minute. Patients received ivabradine 5 mg twice a day with a goal of 7.5 mg twice a day versus placebo. Most patients were also on&#x000a0;beta-blocker therapy. Ivabradine did not affect the primary composite endpoint of cardiovascular mortality, hospital admissions for myocardial infarctions, or worsening heart failure. In patients with heartbeats&#x000a0;of 70 or greater,&#x000a0;ivabradine reduced hospital admissions due to fatal or non-fatal myocardial infarction.&#x000a0;</p>
        <p>SIGNIFY was a randomized trial that tested the addition of ivabradine to standard therapy in patients with&#x000a0;stable coronary artery disease but no heart failure. Patients had to be at least 55 years old with a heart rate&#x000a0;of 70 beats or more.&#x000a0;The goal heart rate&#x000a0;was 55 to 60 beats per minute. Patients received&#x000a0;10 mg&#x000a0;of&#x000a0;ivabradine twice a day or a placebo. The primary endpoint was a composite of death or nonfatal myocardial infarction.&#x000a0;After 28 months, there was no significant difference between ivabradine and placebo. Bradycardia occurred more with ivabradine compared to placebo. The primary endpoint was higher in patients in the ivabradine group who initially had angina that limited activity.</p>
      </sec>
      <sec id="article-41577.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effects include bradycardia, atrial fibrillation, high blood pressure, and phosphenes.</p>
        <p>Ivabradine can cause bradycardia,&#x000a0;sinus arrest, and heart block. Sinus node dysfunction, first- or second-degree atrioventricular block, bundle branch block, ventricular dyssynchrony, and&#x000a0;or concomitant use of other heart-rate reducing drugs increase the risk of bradycardia.&#x000a0;In the SHIFT trial, symptomatic bradycardia occurred in 5% of patients taking ivabradine&#x000a0;compared to 1% in the placebo group. Asymptomatic bradycardia occurred in 6% of patients on ivabradine compared to 1% in the placebo group. Bradycardia led to permanent withdrawal from the study in 1% of patients on ivabradine and less than 1% of those in the placebo group.</p>
        <p>Ivabradine is metabolized by CYP3A4. Concomitant use of verapamil or diltiazem with ivabradine should be avoided. Verapamil and diltiazem are CYP3A4 inhibitors; they increase ivabradine levels and hence the risk of bradycardia.&#x000a0;</p>
        <p>QT prolongation, torsade de pointes, and other arrhythmias may occur&#x000a0;as a result of ivabradine-induced bradycardia.&#x000a0;&#x000a0;</p>
        <p>Ivabradine&#x000a0;increases the risk of atrial fibrillation.&#x000a0;Discontinue ivabradine if atrial fibrillation occurs.</p>
        <p>Visual effects (phosphenes) were observed in clinical trials.&#x000a0;It&#x000a0;has been proposed that this is due to&#x000a0;ivabradine's inhibition of I(h) current in the retina.&#x000a0;In the SHIFT trial, known phosphenes occurred in 3% of patients taking the ivabradine compared to less than 1% in the placebo group. This difference in the occurrence of phosphenes was statistically significant.</p>
        <p>Ivabradine&#x000a0;has been shown to cause fetal toxicity&#x000a0;in animal studies.</p>
        <p>Postmarketing adverse effects of ivabradine include syncope, hypotension, angioedema, erythema, rash, pruritis vertigo, and diplopia.</p>
      </sec>
      <sec id="article-41577.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Ivabradine is contraindicated in the following situations:</p>
        <list list-type="bullet">
          <list-item>
            <p>Decompensated heart failure</p>
          </list-item>
          <list-item>
            <p>Blood pressure less than 90/50</p>
          </list-item>
          <list-item>
            <p>Conduction abnormalities, e.g., sick sinus syndrome, sinoatrial block, or third-degree AV block, unless a pacemaker determines the heart rate</p>
          </list-item>
          <list-item>
            <p>Severe liver impairment</p>
          </list-item>
          <list-item>
            <p>Patients taking cytochrome P450 3A4 (CYP3A4) inhibitors</p>
          </list-item>
          <list-item>
            <p>Resting heart rate less than 60 before therapy initiation</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41577.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <list list-type="bullet">
          <list-item>
            <p>Monitor cardiac rhythm</p>
          </list-item>
          <list-item>
            <p>Monitor heart rate</p>
          </list-item>
          <list-item>
            <p>Monitor for symptoms of bradycardia</p>
          </list-item>
          <list-item>
            <p>Monitor pregnant women for preterm birth with chronic heart failure in the third trimester of pregnancy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41577.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Fetuses of pregnant rats had embryo-fetal toxicity and cardiac teratogenic effects when treated at exposures 1 to 3 times the human exposures at the maximum recommended human dose.&#x000a0;No adequate studies of&#x000a0;ivabradine in pregnant women provide information on the drug's possible risk to the mother or fetus. Contraception is recommended in female patients taking ivabradine.</p>
      </sec>
      <sec id="article-41577.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Ivabradine&#x000a0;is&#x000a0;FDA-approved in the United States&#x000a0;for use in patients with symptoms due to stable heart failure&#x000a0;and an ejection fraction of 35% or less to reduce their risk of hospital admission for worsening heart failure. The management of patients with heart failure is usually by an interprofessional team that includes a cardiologist, intensivist, internist, nephrologist, pulmonologist, family clinician, nursing staff, and pharmacist. Healthcare providers who prescribe ivabradine should monitor the patient's heart rate regularly. The drug can cause bradycardia, and concomitant beta-blocker agents are not recommended.<xref ref-type="bibr" rid="article-41577.r9">[9]</xref><xref ref-type="bibr" rid="article-41577.r10">[10]</xref>&#x000a0;Interprofessional communication and coordination will increase the effectiveness of ivabradine therapy while minimizing adverse effects and interactions, thereby improving patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-41577.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41577&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41577">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/41577/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=41577">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-41577.s11">
        <title>References</title>
        <ref id="article-41577.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krajcirovicova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aziriova</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Repova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Adamcova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paulis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Simko</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Ivabradine does not impair anxiety-like behavior and memory in both healthy and L-NAME-induced hypertensive rats.</article-title>
            <source>Physiol Res</source>
            <year>2018</year>
            <month>Dec</month>
            <day>31</day>
            <volume>67</volume>
            <issue>Suppl 4</issue>
            <fpage>S655</fpage>
            <page-range>S655-S664</page-range>
            <pub-id pub-id-type="pmid">30607972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41577.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ide</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohtani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Higo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawasaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tsutsui</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Ivabradine for the Treatment of Cardiovascular Diseases.</article-title>
            <source>Circ J</source>
            <year>2019</year>
            <month>Jan</month>
            <day>25</day>
            <volume>83</volume>
            <issue>2</issue>
            <fpage>252</fpage>
            <page-range>252-260</page-range>
            <pub-id pub-id-type="pmid">30606942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41577.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sathyamurthy</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Newale</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications.</article-title>
            <source>Indian Heart J</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>70 Suppl 3</volume>
            <issue>Suppl 3</issue>
            <fpage>S435</fpage>
            <page-range>S435-S441</page-range>
            <pub-id pub-id-type="pmid">30595304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41577.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pavasini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Camici</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Crea</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Danchin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Manolis</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Marzilli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosano</surname>
                <given-names>GMC</given-names>
              </name>
              <name>
                <surname>Lopez-Sendon</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Balla</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Anti-anginal drugs: Systematic review and clinical implications.</article-title>
            <source>Int J Cardiol</source>
            <year>2019</year>
            <month>May</month>
            <day>15</day>
            <volume>283</volume>
            <fpage>55</fpage>
            <page-range>55-63</page-range>
            <pub-id pub-id-type="pmid">30538056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41577.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Osmanska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jhund</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Contemporary Management of Heart Failure in the Elderly.</article-title>
            <source>Drugs Aging</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-146</page-range>
            <pub-id pub-id-type="pmid">30535931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41577.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ennezat</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Le Jemtel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hallas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Outcome postponement as a potential patient centred measure of therapeutic benefit: examples in cardiovascular medicine.</article-title>
            <source>Acta Cardiol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-19</page-range>
            <pub-id pub-id-type="pmid">30513258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41577.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badu-Boateng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jennings</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hammersley</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The therapeutic role of ivabradine in heart failure.</article-title>
            <source>Ther Adv Chronic Dis</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>11</issue>
            <fpage>199</fpage>
            <page-range>199-207</page-range>
            <pub-id pub-id-type="pmid">30364460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41577.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>de Arag&#x000e3;o Miguita</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tierie</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zytinski</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baena</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis.</article-title>
            <source>Int J Clin Pharm</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>1443</fpage>
            <page-range>1443-1453</page-range>
            <pub-id pub-id-type="pmid">30173307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41577.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birkhoelzer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zachariah</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rowell</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Ivabradine tolerability in heart failure.</article-title>
            <source>J Geriatr Cardiol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>708</fpage>
            <page-range>708-709</page-range>
            <pub-id pub-id-type="pmid">30534146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41577.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodd</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lampert</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>The Use and Indication of Ivabradine in Heart Failure.</article-title>
            <source>Heart Fail Clin</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>493</fpage>
            <page-range>493-500</page-range>
            <pub-id pub-id-type="pmid">30266358</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
